非酒精性脂肪性肝病包括肝硬化和肝细胞癌的肝脏结局。
Hepatic Outcomes of Nonalcoholic Fatty Liver Disease Including Cirrhosis and Hepatocellular Carcinoma.
机构信息
Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, MD, USA; Liver Transplant Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
出版信息
Clin Liver Dis. 2023 May;27(2):211-223. doi: 10.1016/j.cld.2023.01.019. Epub 2023 Mar 9.
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide and represents a significant cause of cirrhosis and hepatocellular carcinoma (HCC). Almost 20% of patients with NAFLD and advanced fibrosis develop cirrhosis, of which 20% can progress to decompensated liver stage. Although patients with cirrhosis or fibrosis continue to have a high risk for HCC progression, growing evidence shows that NAFLD-HCC can develop even in the absence of cirrhosis. Current evidence characterizes NAFLD-HCC primarily as a condition with late presentation, lower response to curative therapy, and poor prognosis.
非酒精性脂肪性肝病（NAFLD）是全球最常见的慢性肝病，也是肝硬化和肝细胞癌（HCC）的重要病因。近 20%的 NAFLD 伴晚期纤维化患者会发展为肝硬化，其中 20%可能进展为失代偿性肝期。尽管肝硬化或纤维化患者仍存在 HCC 进展的高风险，但越来越多的证据表明，即使没有肝硬化，NAFLD-HCC 也可能发生。目前的证据主要将 NAFLD-HCC 描述为一种晚期表现、对治愈性治疗反应较差和预后不良的疾病。
Zotero 插件